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ABSTRACT 
 
This study compared the relative effectiveness and safety of non-vitamin K antagonists oral 
anticoagulants (NOACs) versus warfarin in elderly Medicare beneficiaries with NVAF and 
diabetes mellitus (DM). 
A retrospective cohort study using 2014 - 2016 5% national Medicare data was undertaken. NVAF 
patients with DM aged ≥65 years having at least one prescription for NOACs (dabigatran, 
rivaroxaban, apixaban, and edoxaban) or warfarin between July, 2014 and December, 2015 were 
selected from the database. Date of first NOAC or warfarin prescription was defined as the index 
date. Patients initiating NOACs were 1:1 matched to warfarin patients on propensity score and 
index date. Stratified Cox proportional hazards models were used to estimate the clinical outcomes 
among patients initiating NOAC therapy versus warfarin therapy in the matched cohort. 
 The matched sample consisted of 4578 patients (2291 in each group). NOACs were found 
to significantly reduce the risk of stroke/SE compared to warfarin (Hazard Ratio (HR): 0.373, 95% 
confidence interval (CI): 0.247 - 0.564, p<0.001); but, no significant difference was seen between 
NOACs and warfarin in terms of reducing the risk of MI (HR: 0.864, CI: 0.594 – 1.257, p=0.446). 
NOACs were found to significantly reduce the risk of ICH (HR: 0.500, CI: 0.300 – 0.834, p=0.008) 
and OB (HR: 0.608, CI: 0.424 – 0.870, p=0.007); but no difference was seen in the risk of MGB 
(HR: 0.862, CI: 0.640 – 1.160, p=0.326) between NOACs and warfarin. NOACs were also found 
to reduce the risk of all-cause mortality (HR: 0.783, CI:0.656 – 0.873, p=0.007). The composite 
of effectiveness and safety outcomes, and all-cause mortality was statistically significant proving 
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superior overall effectiveness and safety of NOAC therapy to warfarin therapy in terms of risk 
reduction (HR:0.685, CI:0.587 – 0.801, p<0.001).  
 Oral anticoagulation therapy with NOACs was found to be more effective than warfarin 
therapy. Results of this study may assist in clinical decision-making about anticoagulation 
therapies used in elderly NVAF patients with DM. 
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CHAPTER I: BACKGROUND 
INTRODUCTION 
Atrial fibrillation (AF) is the most common heart rhythm disorder in the United States 1. The annual 
prevalence of AF in the US population was estimated at 5.2 million in 2010 and projected to 
increase to 12.1 million by 2030, corresponding to an annual growth rate of 4.3 percent 2. 
Advancing age is the most prominent risk factor for AF with a 1-in-4 lifetime risk after age 40 
years 3,4.  The Framingham study reported a five-fold increase in the risk of stroke with advancing 
age in AF patients 5, while the Scottish Renfrew/Paisley study with a 20-year follow-up found a 
three-fold increase in the risk of stroke among AF patients 6.  Diabetes is another independent risk 
factor of AF with a prevalence of ranging from 24 – 30 percent among AF patients 7,8. The 
relationship between diabetes mellitus and AF is mutual and reciprocal. Incidence of AF in patients 
with diabetes has been reported around 14.9% 9.  An observational study assessing the impact of 
diabetes mellitus (DM) on AF reported that over a mean follow-up of 7.2 ± 2.8 years, diabetic 
patients without AF at baseline had an age- and sex-adjusted incidence rate of AF 9.1 per 1,000 
person-years (95% CI: 8.6–9.7) compared with a rate of 6.6 (95% CI: 6.2–7.1) among nondiabetic 
patients 10. Among diabetes patients, AF was independently associated with a 61 percent greater 
risk for vascular death and all-cause mortality and higher risks for cardiovascular death and heart 
failure when compared with patients without AF 11. 
Since 1950s, vitamin K antagonists (VKA) such as warfarin and low molecular weight 
heparins (LMWH) were used for anticoagulation treatment in AF patients. A meta-analysis of 
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thromboembolic and bleeding outcomes by Hart et al. comparing warfarin to antiplatelet drugs in 
AF patients found warfarin to reduce the risk of stroke by 60 percent 12. Bleeding is the most 
common side effect of warfarin and occurs in up to 41 percent of patients treated with warfarin. 
Additionally, its use can be cumbersome because of its food and drug interactions, dose 
adjustment, and need for constant monitoring through laboratory testing 12,13. Literature reports 
VKA therapy discontinuation rates of nearly 30-60 percent among patients with AF, and patients 
who discontinued therapy had significantly poor anticoagulation control in terms of poor  
International Normalized Ratio (INR), lesser Time in Therapeutic Range (TTR), and resultant 
underanticoagulation 14–16.  Beginning 2010, a new class of oral anticoagulants, non-vitamin K 
antagonists oral anticoagulants (NOACs) were introduced in the US market. Between 2010 and 
2015, the US Food and Drug Administration (FDA) approved four NOACs – dabigatran, apixaban, 
rivaroxaban and edoxaban – indicated for thromboprophylaxis in patients with non-valvular AF 
(NVAF). Of these, dabigatran is a direct thrombin inhibitor while others are factor Xa inhibitors. 
Direct targeting of factor Xa and thrombin provides a faster onset of action compared to warfarin, 
predictable pharmacokinetics and pharmacodynamics with a lesser potential for food and drug 
interactions allows for better fixed dosing schedules without dietary restrictions or routine 
coagulation monitoring 13. 
Several randomized clinical trials (RCTs) have demonstrated that NOACs have at least 
equivalent efficacy and safety as compared to warfarin in terms of stroke/systemic embolism (SE) 
reduction and major hemorrhage rates, in patients with NVAF 17–20. Results of phase III RCTs 
conducted in a sub-group of NVAF patients with diabetes report that NOACs have superior 
efficacy compared to warfarin. However, the safety profile of NOACs present a complex scenario. 
Bleeding events of NOACs were found to vary by a specific NOAC and dosage. While high dose 
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edoxaban (60 mg) 20, as compared to low dose edoxaban (30 mg) and warfarin, reduced major 
bleeding in both NVAF patients with and without diabetes, apixaban 21 reduced major bleeding 
only among nondiabetic patients with NVAF, with no significant interaction by diabetes status. 
Interestingly, in patients with diabetes and NVAF, dabigatran and rivaroxaban were not 
significantly different from warfarin in reducing the risk of major bleeding, and there was no 
significant interaction by diabetes status 22,23. 
Proven efficacy and safety in RCTs, and the pharmacological characteristics of NOACs 
contribute to their practical advantages over traditional VKA therapy in reducing thromboembolic 
risk 13. With widespread adoption of NOACs in the routine practice, several observational studies 
have been conducted to assess real world effectiveness and safety of these drugs 24–31. These studies 
report a comparable or superior performance of NOACs to warfarin in stroke/SE reduction in 
patients with AF, but a variation in bleeding outcomes. Apixaban was found to have the lowest 
bleeding risk as compared to warfarin followed by dabigatran and rivaroxaban. Rivaroxaban was 
associated with higher bleeding risk as compared to warfarin, especially in elderly population32–
34. 
While research has been conducted in the geriatric population with AF and diabetic patients 
with NVAF, no real world evidence is available in comparing the effectiveness and safety of 
NOAC therapy with warfarin in elderly NVAF patients with comorbid diabetes 35. NVAF patients 
with DM are at an increased risk of thromboembolic and bleeding events due to the synergistic 
effect of DM and aging. Given the complex clinical interactions between AF and diabetes, care 
for elderly NVAF patients with DM can be complicated. Evidence obtained through this 
observational study may assist in clinical decision-making pertaining to the choice of oral 
anticoagulation therapy in patients with simultaneous presence of both AF and DM 35,36. This study 
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assessed the comparative effectiveness and safety of NOAC therapy versus traditional warfarin 
therapy in elderly NVAF patients with concomitant diabetes mellitus using 5% national Medicare 
data. 
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LITERATURE REVIEW 
Atrial Fibrillation – Pathophysiology and Etiology 
According to the American Heart Association, atrial fibrillation (AF) is defined as “a quivering or 
irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-
related complications.”1 It is a type of supraventricular tachycardia which starts as brief periods 
of abnormal beating which become longer and possibly constant over time. The arrhythmia is 
characterized by chaotic, electrical conduction in the atria. In AF, the cardiac neuronal signals 
begin in another part of atria or near the pulmonary veins instead of sinoatrial (SA) node. Spreading 
of faulty neuronal signals in a rapid, disorganized way can cause the atria to fibrillate. These signals 
then flood the atrioventricular (AV) node causing the ventricles to beat faster.  
AF may be classified based on etiology, depending on whether it occurs without 
identifiable etiology in patients with a structurally normal heart (lone AF), or whether it 
complicates hypertensive, valvar, ischemic or other structural heart disease. Lone AF accounts for 
about 15% of the total AF cases.37 AF maybe termed as non-valvular AF (NVAF) in absence of 
rheumatic mitral valve disease, a prosthetic heart valve, or mitral valve repair. If AF occurs in the 
setting of a primary condition that maybe the cause of the AF such as acute myocardial infarction, 
cardiac surgery, pericarditis, myocarditis, hyperthyroidism, pulmonary embolism, pneumonia, or 
other acute pulmonary disease, it may be classified as secondary AF.37  
Based on the temporal pattern of the arrhythmia, a system of clinical classification has been 
recommended. The American College of Cardiology (ACC), American Heart Association (AHA), 
and the European Society of Cardiology (ESC) recommend in their guidelines the following 
classification system based on simplicity and clinical relevance.38 Patients presenting to medical 
attention may have a first detected episode of AF or, if previous episodes have been documented, 
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recurrent arrhythmia. Episodes themselves may be paroxysmal, if they terminate spontaneously, 
usually within seven days, or persistent if the arrhythmia continues requiring electrical or 
pharmacological cardioversion for termination. AF that cannot be successfully terminated by 
cardioversion, and longstanding (>1 year) AF, where cardioversion is not indicated or has not been 
attempted, is termed permanent. 
Epidemiology of AF 
AF is the most common clinically significant cardiac arrhythmia in the US.5 Global prevalence of 
AF in 2010 was estimated to be around 33.5 million (20.9 million males and 12.6 million females). 
AF was found to be more prevalent among men than women. Between 1990-2010, the global 
incidence rate increased from 60.7 per 1000 person-years in males to 77.5 per 1000 person-years, 
and from 43.8 to 59.5 per 1000 person-years in females.39 The annual prevalence of AF in the US 
population was estimated at 5.2 million in 2010 and projected to increase to 12.1 million by 2030, 
corresponding to a growth rate of 4.3%.2 The prevalence of AF was found to increase with age, 
and it is estimated that over 80% of US adults with AF are 65 years or older and approximately 
37% are 80 years or older.40 Aging is associated with regional conduction slowing, anatomically 
determined conduction delay at the crista, and structural changes that include areas of low voltage 
in cardiac musculature. In addition, impairment of sinus node function and an increase in atrial 
refractoriness occurs with aging. This electrical and structural remodeling may explain the 
increased propensity to AF with aging.41  
Apart from the elderly population, approximately 12-30% of AF has been reported to occur 
in athletes and younger individuals as “lone AF” (AF with no underlying heart disease).40 These 
patients typically have few comorbidities, yet are usually very symptomatic upon presentation. 
Researchers from the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study 
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(N=17,974) reported that African Americans and Latinos were less likely diagnosed with AF when 
compared with Whites with rates of 3.6%, 2.5%, and 84.7%, respectively. Others have supported 
the finding of a lower prevalence of AF in African Americans, Hispanics, and Asians compared to 
Whites.40,42–44  
Economic and Disability Burden Of AF 
High mortality and morbidity associated with AF imposes a significant financial burden. However, 
coexistent cardiovascular and non-cardiovascular comorbidities make estimation of direct 
healthcare costs attributable to AF difficult. The total costs of AF were estimated to be around 6.65 
billion USD (2005 dollars). Nearly 75% of the costs of AF represent the direct and indirect costs 
associated with hospitalization. Hospital costs are higher among AF patients not only because of 
the initial stay but also because of the frequent need for readmission.45 One study reported that 
medical costs for people with AF were $8,705 higher than people without AF.46 Stroke and 
hemorrhage associated with non-valvular atrial fibrillation (NVAF) represent a substantial fraction 
of the economic burden. A retrospective analysis of Medicare beneficiaries found that the 
hemorrhage and stroke-related cost per NVAF patient was $64,956 and $63,781 USD respectively 
as compared to $35,474 per NVAF patient without stroke or hemorrhage.47  
The pathophysiology of AF predisposes patients with AF at a greater thromboembolic risk. It is 
associated with a 3- to 5- fold increase in risk of stroke and causes 15%–20% of ischemic strokes, 
which occur when blood flow to the brain is blocked by a clot or by fatty deposits called plaque in 
the blood vessel lining.42,6 Strokes caused by complications from AF tend to be more severe than 
strokes with other underlying causes.42 AF is a chronic, debilitating disorder which has a 
progressive negative impact on patients’ quality of life. Burden associated with AF, measured as 
disability adjusted life-years (DALYs), increased by 18.8% in males and 18.9% in females, from 
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1990 to 2010. Mortality associated with AF was greater among women, and increased 2-fold and 
1.9-fold in males and females respectively from 1990-2010.39 The growing epidemic of AF is 
responsible for about 750,000 hospitalizations annually and contributes to an estimated 130,000 
deaths each year.48  
Risk Factors Of AF 
Other than structural heart diseases, other factors involved in initiation or maintenance of AF may 
include inflammation, atrial ischemia, autonomic nervous system activity, atrial dilation, and 
structural fibrosis associated with aging. Familial AF is well described, although at present this 
subtype of AF is rare.43 Over the past decade, population-based studies have suggested that AF is 
a heritable disease.49,50  
While age and genetics are non-modifiable risk factors for AF, several modifiable risk 
factors for AF have been identified in the literature. Many modifiable risk factors associated with 
atherosclerotic vascular disease have also been associated with development of AF.51 Increased 
left atrial pressure, as seen with hypertension and some valvular diseases, have been hypothesized 
to provide a substrate for AF, but the causal link remains unclear. This might explain higher 
incidence of AF seen among hypertensive patients.52 Obesity has been found to be associated with 
increase pericardial fat volume and increased epicardial fat thickness, which may lead to altered 
atrial electrophysiology and sympathovagal imbalance of the atria.53,54 Clinically, epicardial fat 
has been associated with AF.55 Obstructive sleep apnea is highly prevalent among AF patients. In 
a prospective analysis, approximately 50% of AF patients had OSA, as compared with 32% of 
controls.56 Mechanisms by which OSA contributes to AF risk include intermittent nocturnal 
hypoxemia/ hypercapnia, surges in sympathetic tone and blood pressure during apneic episodes, 
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and increased inflammation. These factors may contribute to left atrial remodeling and chamber 
dilation, contributing to development of AF.57,58  
Diabetes is an independent risk factor for AF. 59,60 Both AF and type 2 diabetes are chronic 
diseases that increase in prevalence and severity with age and are each independently associated 
with an increased risk for stroke, heart failure, and death. In 2015, 30.3 million Americans, or 9.4% 
of the population, had diabetes. Among older Americans aged 65 years and older, nearly 25.2% or 
12.0 million had diabetes.61 The annual prevalence of AF in the US population was estimated at 
5.2 million in 2010 and projected to increase to 12.1 million by 2030, corresponding to a growth 
rate of 4.3%.2 Significant research has been conducted to understand the pathophysiological 
association between diabetes and AF. Diabetes is associated with numerous metabolic defects 
including insulin resistance, impaired glucose tolerance, proinflammatory mediators, 
abnormalities of hemostasis, fibrinolysis, angiogenesis and extracellular matrix turnover.62–64 All 
of these metabolic changes lead to endothelial dysfunction, abnormal activation of the renin-
angiotensin-aldosterone system (RAAS) and acceleration of atherogenesis, which could be 
responsible for AF occurrence. Diabetes could also cause structural, electrical, electromechanical 
and autonomic remodeling.65  
Literature reports that diabetes is associated with a 35% to 60% relative increase in the risk 
for developing AF after adjustment for confounders.66–68 Also, AF patients with diabetes were 
found to have higher mortality and higher rates of myocardial infarction as compared to those with 
diabetes mellitus alone.69 The Action in Diabetes and Vascular Disease: preterAx and diamicroN-
MR Controlled Evaluation Trial found that in patients with type 2 diabetes, after adjusting for 
confounders, AF was independently associated with a 61% greater risk for death and all-cause 
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mortality and higher risks for cardiovascular death and heart failure when compared with patients 
without AF.11  
Thromboembolic Risk Estimation In AF 
Given the diversity of risk factors involved in development or exacerbation of AF and 
thromboembolism, several risk scoring systems have been developed to calculate and stratify the 
risk of stroke. The risk of stroke is estimated using the CHADS2 score or the CHA2DS2-VASc 
score. These scores calculate the risk of stroke by assigning specific weights to major risk factors 
of AF which can cause stroke. The 2014 American Heart Association (AHA) /American College 
of Cardiology (ACC) /Heart Rhythm Society (HRS) guidelines and the 2016 European Society of 
Cardiology (ESC) guidelines on AF recommend using the CHA2DS2-VASc score for 
thromboembolic risk estimation.43,70 However, the major clinical trials of non-vitamin K 
antagonists oral anticoagulants (NOACs) – the RE-LY trial (dabigatran versus warfarin), the 
ARISTOTLE trial (apixaban versus warfarin), the ROCKET-AF trial (rivaroxaban versus 
warfarin) and the edoxaban versus warfarin trial – have used CHADS2 score  for estimating the 
thromboembolic risk.17–20 
The CHADS2 score system is based upon a cumulative scoring system focusing on five 
major risk factors: congestive heart failure, hypertension, age ≥ 75 years, diabetes, and history of 
stroke or transient ischemic attack.71 Each factor is scored 1, except the cerebral events scored 2 
points, reflecting their increased weight. The original validation of the score classified CHADS2 
score of 1-2 as moderate, and CHADS2 > 2 as high risk.
71 The CHA2DS2-VASc score is also based 
upon a cumulative scoring system focusing on congestive heart failure, hypertension, age >75 
years [doubled], diabetes, stroke [doubled], vascular disease, age 65-74 years, sex category 
[female] to estimate the risk for stroke in patients with AF.72,73 Both, the 2014 AHA/ACC/HRS 
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guidelines and the 2016 ESC guidelines on AF recommend using CHA2DS2-VASc score for 
calculation of thromboembolic risk since it is more comprehensive and considers more risk factors 
in predicting the risk of stroke.43,70,74   
Anticoagulation in AF 
Since 1950s, warfarin, a vitamin K antagonist (VKA), has been the mainstay treatment 
thromboprophylaxis in NVAF (NVAF) patients.43 It is an oral medication to be administered once 
daily. Treatment is monitored using prothrombin time (PT) or international normalized ratio (INR) 
to calculate the time for blood clotting. Bleeding is the most common side effect of warfarin and 
occurs in up to 41% of patients treated with warfarin, with rates of major bleeding in practice of 
about 7 – 8% per year.75,76 An observational study reported that warfarin-related hemorrhage rates 
were 11.8% among older adults and were highest during first 30 days of warfarin therapy.14  Other 
rare yet severe adverse effects include tissue necrosis, calciphylaxis, and systemic atheroemboli 
and cholesterol microemboli.77 Thus, although the treatment with warfarin can reduce the risk of 
stroke by 60% to 70%, its use can be cumbersome because of its food and drug interactions, 
hemorrhage, dose adjustment and need for constant monitoring through laboratory testing.43,77 
Recently, the US Food and Drug Administration approved a new class of non-vitamin K 
antagonist oral anticoagulants (NOACs). NOACs are direct thrombin (dabigatran) or factor Xa 
(rivaroxaban, apixaban, edoxaban) inhibitors indicated for oral anticoagulation among NVAF 
patients. Currently, four NOACs are available in the market – dabigatran, apixaban, rivaroxaban 
and edoxaban.  
Phase III clinical trials of these NOACs have demonstrated at least equivalent efficacy and 
safety as compared to warfarin in terms of stroke/systemic embolism (SE) reduction and major 
hemorrhage rates, respectively in patients with NVAF.17–20 For example, in the ARISTOTLE trial 
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comparing apixaban to warfarin, apixaban at a dose of 5 mg twice daily was found superior to 
warfarin in preventing stroke/SE (1.27% per year vs 1.60% in warfarin group, hazard ratio with 
apixaban- 0.79; 95% confidence interval [CI], 0.66 to 0.95; P<0.001 for noninferiority; P = 0.01 
for superiority), caused less bleeding (2.13% per year vs 3.09% per year in the warfarin group, 
hazard ratio, 0.69; 95% CI, 0.60 to 0.80; P<0.001) and had lower mortality rates (3.52% vs 3.94%, 
(hazard ratio, 0.89; 95% CI, 0.80 to 0.99; P = 0.047).17 
Comparison of NOACs and VKAs 
The pharmacological characteristics of NOACs contribute to their practical advantages over VKA 
therapy in reducing thromboembolic risk.13 Direct targeting of factor Xa and thrombin provides a 
faster onset of action, predictable pharmacokinetics and pharmacodynamics with a lesser potential 
for food and drug interactions allows for better fixed dosing schedules without dietary restrictions 
or routine coagulation monitoring. However, there are disadvantages to NOAC therapy as well. 
Unlike VKAs, NOACs are eliminated renally; renal impairment affects the efficacy of NOACs 
and increases the associated risk of bleeding.14,75,76 Hence, NOACs are not indicated in patients 
with creatinine clearance (CrCl) < 15 mL/min (apixaban, edoxaban and rivaroxaban) and < 30 
mL/min (dabigatran).78–81 NOACs have a faster onset of action with a short elimination half-life. 
Hemostasis is restored approximately 12–24 h after cessation of NOACs, assuming normal renal 
function. If a patient is experiencing non-life-threatening bleeding, discontinuation of the NOACs 
and supportive management should suffice. However, in case of life-threatening bleeding, in 
addition to discontinuation of the NOAC, administration of a reversal agent should be 
considered.82 Currently, only one reversal agent, idarucizumab is available in the market for 
reversal of dabigatran-induced anticoagulation.83 Another factor Xa inhibitor reversal agent- 
andexanet alfa has demonstrated efficacy in preclinical studies. Similarly, a synthetic small 
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molecule antidote ciraparantag has shown efficacy in reversal of anticoagulation of all NOACs in 
rat models.84 Till these specific reversal agents become available, life-threatening bleeding with 
NOACs can be a potential deterrent of use. 
Indirect mechanism of action of VKAs which results in slower onset and offset of 
anticoagulation effect, inherent prothrombotic effect of VKAs which increases the risk of stroke 
in the first 30 days on therapy initiation, narrow therapeutic range necessitating constant 
monitoring of international normalized ratio (INR) and food and drug interactions with VKA 
therapy are contributing to their under-prescription in patients with high risk of stroke and systemic 
embolism.13 In the GARFIELD-AF registry, 38.0% of patients with a CHADS2 score ≥2 did not 
receive anticoagulant therapy; 7.2% of patients with AF and CHADS2 ≥2 had refused treatment 
for various reasons, including inconvenience of regular blood tests, dietary restrictions, bleeding 
risk and an under-appreciation or lack of knowledge regarding the risk of stroke.85  As well as 
being unwilling to start VKA therapy, many patients with AF who initiated VKA therapy 
discontinue or are non-adherent. For example, of 125,195 patients newly diagnosed with AF in 
Canada from 1997 to 2008, 9% did not collect their second prescription of warfarin within the first 
half year and 32% discontinued therapy within 1 year, rising to 43% at 2 years and 61% at 5 
years.14 Similarly, in a US study, more than one in four new warfarin starters discontinued therapy 
within a year.15 In another study, 40% of patients were non-adherent to VKA therapy (>20% of 
days with missed doses or >10% of days where extra doses were taken in addition to the prescribed 
dose), and this percentage was significantly associated with poor anticoagulation control.16  These 
limitations and inconvenience with VKA therapy and the equivalent efficacy of NOACs, faster 
onset of action, lack of food and drug interactions, convenient and hassle-free monitoring of 
19 
 
therapy has made NOACs the first choice of treatment for thromboprophylaxis in patients with 
NVAF.43,70 
Effectiveness of NOACs in-the-real-world studies 
The safety and efficacy of NOACs seen in the randomized clinical trials may not always reflect in 
real world practice because of the differences in the patient populations, the intensity of follow-
up, and the variations in care received by the patients. Several systematic reviews and meta 
analyses of randomized clinical trials and observational studies have been conducted to compare 
the efficacy and safety of NOACs versus VKAs in patients with AF.86–90  
Lin et al. found NOACs to be associated with lower risk systemic stroke/embolism and 
intracranial bleeding as compared to warfarin. Dabigatran 150 mg and rivaroxaban were associated 
with greater risk of major bleeding in the elderly population.86  In a systematic review and meta 
analyses of 13 RCTs and 27 observational studies (32 for AF), Almutairi et al. found dabigatran 
and VKAs were comparable for stroke/SE risk in 1 RCT (HR, 0.77 [95% CI, 0.57–1.03]) and 6 
observational studies (HR, 1.03 [95% CI, 0.83–1.27]). Rivaroxaban had a 20% decreased risk of 
stroke/SE in 3 RCTs (HR, 0.80 [95% CI, 0.67–0.95]) compared with VKA, but the effect was 
nonsignificant in 3 observational studies (HR, 0.78 [95% CI, 0.59–1.04]). Apixaban decreased 
stroke/SE risk (HR, 0.79 [95% CI, 0.66–0.95]) compared with VKA in 1 RCT, but edoxaban was 
comparable to VKA (HR, 0.99 [95% CI, 0.77–1.28]) in 1 RCT (no observational studies available 
for apixaban/edoxaban). Dabigatran, apixaban, and edoxaban decreased the risk of hemorrhagic 
stroke, mortality, major bleeding, and ICH by 10% to 71% compared with VKAs but not 
rivaroxaban. 87 Apart from rivaroxaban, all NOACs had a decreased risk of major bleeding. An 
exhaustive review by Raschi et al. found NOACs to be comparable to VKAs in terms of safety, 
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efficacy and effectiveness, and indicated a consistent and clinically relevant reduced risk (more 
than 50%) of intracranial bleeding.88  
With widespread adoption of NOACs in the routine practice, several observational studies 
have been conducted worldwide to assess real world safety and effectiveness of these drugs.24–31 
Since edoxaban was approved in early 2015, these studies have compared only 3 NOACS - 
apixaban, dabigatran and rivaroxaban to warfarin in assessing the effectiveness and safety in AF 
patients.  
Many of these real-world observational studies have been conducted using Danish patient 
registries. All Danish studies found NOACs to be of comparable effectiveness in reducing 
stroke/SE as compared to warfarin. However, the bleeding rates differed between individual 
NOAC.24–27,91 The advantages with NOAC treatment were most pronounced with standard dose in 
patients below 80 years, and with dose reduction in patients aged 80 and above.26  
In the US, real world observational studies to assess effectiveness and safety of NOACs as 
compared to warfarin have been conducted using administrative claims data.28–31 In the 
observational study of elderly NVAF patients using Medicare data, Amin et al. found apixaban 
(HR, 0.40; 95% CI, 0.31-0.53) and rivaroxaban (HR, 0.72; 95% CI, 0.63-0.83) were significantly 
associated with lower risk of stroke/SE compared to warfarin. Apixaban (HR, 0.51; 95% CI, 0.44-
0.58) and dabigatran (HR,0.79; 95% CI 0.69-0.91) were significantly associated with lower risk 
of major bleeding; rivaroxaban (HR, 1.17; 95% CI 1.10-1.26) was significantly associated with 
higher risk of major bleeding compared to warfarin.31 Yao et al. found that for stroke or systemic 
embolism, apixaban was associated with lower risk (hazard ratio [HR] 0.67, 95% CI 0.46–0.98, 
P=0.04), but dabigatran and rivaroxaban were associated with a similar risk (dabigatran: HR 0.98, 
95% CI 0.76–1.26, P=0.98; rivaroxaban: HR 0.93, 95% CI 0.72–1.19, P=0.56). For major 
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bleeding, apixaban and dabigatran were associated with lower risk (apixaban: HR, 0.45, 95% CI 
0.34–0.59, P<0.001; dabigatran: HR 0.79, 95% CI 0.67–0.94, P<0.01), and rivaroxaban was 
associated with a similar risk (HR 1.04, 95% CI 0.90–1.20], P=0.60). All NOACs were associated 
with a lower risk of ICH.30 Thus, there were minor consistencies reported in the differential 
bleeding rates of NOACs amongst themselves and as compared to warfarin.  
Comparison of bleeding rates between NOACs and warfarin 
To facilitate a better understanding of NOAC therapy safety, significant amount of research has 
been conducted to evaluate major bleedings (gastrointestinal, intracranial and other sites) rates 
associated with NOAC therapy.32,33,91–97 Some studies have focused on a specific bleeding rates 
such as gastrointestinal bleeding,94,95,98 while other have looked into major bleeding rates as a 
whole.32,33,91,96,97,99,100  In a systematic review and meta analyses of 16 RCTs and 31 observational 
studies, Roskell et al. reported that the overall median incidence of major bleeding was 2.1 per 100 
patient-years (range, 0.9– 3.4 per 100 patient-years) for RCTs and 2.0 per 100 patient-years (range, 
0.2 –7.6 per 100 patient-years) for observational studies.93 The risk of bleeding increased with age 
and NOAC-related bleeding risk was higher in patients 65 years of age and older.32,95  In almost all 
studies, apixaban was found to have the lowest bleeding risk as compared to warfarin followed by 
dabigatran and rivaroxaban. Rivaroxaban was associated with higher bleeding risk as compared to 
warfarin, especially in elderly population. Adeboyeje et al. found that relative to warfarin, 
dabigatran and apixaban were associated with a 33% lower major bleeding risk, while dabigatran 
and apixaban were associated with a 48% lower risk of major bleeding compared with 
rivaroxaban.100 Xu et al. have ranked NOACs in terms of their gastrointestinal and intracranial 
bleeding risk. Apixaban 5 mg had the lowest gastrointestinal bleeding risk, while apixaban 5 mg, 
dabigatran 110 mg, and edoxaban 30 mg had lowest risk of intracranial bleeding.34  
22 
 
Comparison of NOACs versus warfarin in the elderly population 
Elderly NVAF patients are likely to be more severe and have more comorbidities than their 
younger counterparts.40 An aging heart is characterized by several anatomical changes such as 
regional conduction slowing, atrial remodeling, and structural changes that include areas of low 
voltage in cardiac musculature. In addition, impairment of sinus node function and an increase in 
atrial refractoriness occurs with aging.41 Advancing age is associated with multiple changes in the 
pharmacokinetics of drugs and volume of distribution, albumin concentrations, impaired renal 
function, and gastric acid secretion. Of note, advancing age may result in declining renal function 
and diminished clearance of medications. These patients are also at an increased risk of bleeding 
from anticoagulants.101 Patients aged 65 years and older are predisposed to a greater risk of 
thromboembolic and bleeding events because of their age and require special considerations while 
initiating anticoagulation therapy.  
In separate meta-analyses of NOAC therapy in patients aged 75 years and older, 
researchers found a similar or superior efficacy of NOACs compared to warfarin in patients with 
AF.102,103 A lack of statistical interaction with age in this analysis indicated that the conclusions to 
be drawn from the benefits of NOACs are similar for elderly patients. In a separate study, Sharma 
et al reported a similar or superior efficacy of NOACs as compared to VKA in stroke/SE reduction 
in the elderly. A non-significantly, higher risk of major bleeding than VKA was observed with 
dabigatran 150mg (OR, 1.18, 95% CI, 0.97-1.44) but not with the 110mg dose. Significantly higher 
gastrointestinal bleeding risks with dabigatran 150mg (1.78, 1.35-2.35) and 110mg (1.40, 1.04-
1.90) and lower intracranial bleeding risks than VKA for dabigatran 150mg (0.43, 0.26-0.72) and 
dabigatran 110mg (0.36, 0.22-0.61) were also observed. A significantly lower major bleeding risk 
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compared to VKA was observed for apixaban (0.63, 0.51-0.77), edoxaban 60mg (0.81, 0.67-0.98) 
and 30mg (0.46, 0.38-0.57) while rivaroxaban showed similar risk.89 
Observational studies have been conducted to explore the NOAC therapy outcomes in 
elderly population.31,104–106 Most of these studies found NOACs to be comparable or superior to 
warfarin in reduction of stroke/systemic embolism rates in elderly NVAF patients. However, the 
bleeding rates were different within the NOACs – apixaban had the lowest major bleeding rate 
followed by low-dose dabigatran 110 mg and edoxaban 30 mg and 60 mg. Higher bleeding risk 
was associated with rivaroxaban and high-dose dabigatran 150 mg.  
Comparison of NOACs versus warfarin in the Diabetes sub-group of AF patients 
While NOACs are indicated for thromboprophylaxis in patients with NVAF, their efficacy 
and safety has been tested in different sub-groups of NVAF patients such as diabetes, hypertension 
and chronic kidney disease during the phase III clinical trials.21–23,107–111  
In a meta-analysis of 7 prospective cohort studies and 4 case-control studies, Huxley et al. found 
that DM increased the risk of AF by 40% compared to normal patients.60 In an observational study 
of the HMO diabetes registry, diabetes was found to be an independent risk factor (26% elevated 
risk) for AF among women (HR, 1.26 95% CI, 1.08 –1.46), but diabetes was not a statistically 
significant factor among men (1.09, 0.96 –1.24).10  In two observational studies, Huang et al. and 
Peacock et al. found DM coexisting with NVAF to be associated with an increased risk of 1-year 
all-cause mortality, cardiovascular mortality and a greater incidence of major bleeding.112,113 
Among different patient subgroups, studies have been conducted to evaluate efficacy and 
safety of NOACs in AF patients with coexistent diabetes. A meta-analysis by Ruff et al. of the 
four available NOACs showed no significant association between diabetes and the benefit–risk 
ratio of NOACs in patients with AF.102 However, contradictory results related to hemorrhagic risk 
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have been reported in clinical trials of AF patients with diabetes receiving NOAC therapy. In the 
ARISTOTLE study comparing apixaban to warfarin, apixaban was associated with significantly 
lower hemorrhagic risk as compared to warfarin.21 The RE-LY study comparing dabigatran to 
warfarin showed comparable bleeding risk but a greater risk reduction of thromboembolic events.23 
A significantly reduced rate of intracranial hemorrhage was reported in diabetic patients receiving 
dabigatran 110 mg twice daily compared to warfarin, but a non-significant reduction in diabetic 
patients receiving dabigatran 150 mg twice daily. In the ROCKET-AF study comparing 
rivaroxaban and warfarin, there was no significant association between diabetes and the risk of 
hemorrhagic complications.22  
In another meta-analysis of phase III randomized trials of NOACs versus warfarin in 
diabetic NVAF patients, Patti et al. did not find any interaction between diabetic status and the 
benefits of NOACs was found for the occurrence of ischemic stroke, major bleeding, or intracranial 
bleeding. However, a significant decrease in vascular deaths (1.02% vs. 0.27%) in diabetic NVAF 
patients as compared to non-diabetics (4.97% vs. 5.99% with warfarin) was reported.114  
Significance of The Study 
AF and diabetes, especially type 2 diabetes, have emerged as global epidemics with significant 
effects on morbidity and mortality. The prevalence and incidence of AF increases with age.8 
Approximately 5% of the population over the age of 65 years and 10% over the age of 79 years 
are affected by AF.115 Nearly 24% of the total population with AF has comorbid diabetes.116 Based 
on the meta-analysis of 11 observational studies of 1.6 million patients, diabetes was associated 
with a 40% increased risk for AF.42 Given the complex clinical interactions between AF and type 
2 diabetes and their associated comorbidities, care for these patients can be complicated, and 
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whether the simultaneous presence of both AF and type 2 diabetes deserves special consideration 
with regard to clinical decision making remains unclear.35  
Randomized clinical trials of NOACs have evaluated the efficacy and safety in different 
subgroups of patients such as hypertension, diabetes, heart failure and chronic kidney disease, but 
the idealized conditions of the clinical trials are not always replicated in real-world.98-105 Several 
observational studies have explored the safety and effectiveness of NOACs in the general patient 
population with AF; however, there is a paucity of real-world studies exploring the comparative 
safety and effectiveness of NOACs versus warfarin in different subgroups of NVAF patients. No 
observational study has been conducted to evaluate the safety and efficacy of NOAC therapy in 
elderly NVAF patients with coexistent diabetes. Diabetes and AF are both chronic, severe and 
infrequently reversible diseases with significant economic and disability burden. With NOACs 
becoming the first line of anticoagulation therapy for stroke prevention, it is important and 
necessary to evaluate NOAC therapy outcomes as compared to the traditional warfarin therapy in 
elderly NVAF patients with diabetes. This study seeks to provide information to assist in clinical 
decision-making about the comparative effectiveness and safety of NOAC therapy versus warfarin 
in elderly NVAF patients with coexistent diabetes.  
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RESEARCH OBJECTIVE 
To compare the effectiveness and safety of non-vitamin K antagonists oral anticoagulants 
(NOACs) (dabigatran, rivaroxaban, apixaban, and edoxaban) versus warfarin in elderly Medicare 
beneficiaries with non-valvular atrial fibrillation (NVAF) and diabetes mellitus (DM). 
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CHAPTER II: METHODOLOGY 
DATA SOURCE  
A retrospective cohort study was conducted using the 2014-2016 5% national Medicare 
administrative claims data from the Centers of Medicare and Medicaid Services (CMS). Medicare 
is the federal health insurance program for those aged ≥65 years, people with disabilities, and 
people with end-stage renal disease in the United States, with an estimated 38 million fee-for-
service beneficiaries 117. Medicare administrative claims include information on hospital inpatient, 
outpatient, Medicare carrier, Part D, skilled nursing facility, home health agency, and durable 
medical equipment claims. The medical claims are coded using International Classification of 
Disease, 9th Revision, Clinical Modification (ICD-9-CM) and 10th Revision (ICD-10-CM), 
Current Procedural Terminology, or Healthcare Common Procedure Coding System codes. 
Pharmacy claims include information on drugs dispensed using the National Drug Code coding 
system.  
Study Population 
Elderly patients aged ≥65 years with NVAF and diabetes mellitus having at least one pharmacy 
claim for a NOAC (dabigatran, rivaroxaban, apixaban or edoxaban) or warfarin between July 1, 
2014 to December 31, 2015 were selected. Index date was defined as the date of first new 
prescription claim for a NOAC or warfarin between July 1, 2014 to December 31, 2015. To ensure 
the inclusion of only treatment-naïve NOAC and warfarin users, a rolling pre-index 
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period of six months was used to confirm that the patients did not have a prior exposure to NOACs 
or warfarin. The time period from index date to December 31, 2016 was used for identification of 
outcomes; thus, ensuring that each patient had at least 12 months of follow-up period.  
Patients were required to have continuous medical (Part A and Part B) and pharmacy (Part 
D) enrolment for six months prior to the index date. In Medicare data, beneficiary Part A and Part 
B enrollment information is available as single variables showing number of months a beneficiary 
was enrolled in Medicare Part A and Part B in a given calendar year. Since, a rolling pre-index 
period was used, patients having pre-index period spread across 2014 and 2015 were required to 
have at least three months of Part A and Part B continuous enrollment in each calendar year. 
Patients were required to have one or more inpatient or outpatient claims carrying a diagnosis code 
for NVAF (ICD-9-CM code 427.31 and ICD-10-CM code I48.0, I48.1, I48.2, I48.91)118 and have 
at least two outpatient claims or at least one inpatient claim for diabetes (ICD-9-CM code 250.* 
and ICD-10-CM code E11.*) within the six-month pre-index period.119  
Patients with evidence of valvular heart disease, heart valve replacement or surgery, venous 
thromboembolism (VTE), pulmonary embolism, transient AF (pericarditis, hyperthyroidism, 
thyrotoxicity), and end-stage renal disease in the pre-index period were excluded from the study. 
Patients who underwent hip or knee replacement surgery within six weeks prior to the index date 
were excluded. This study also excluded beneficiaries with dual eligibility for Medicare and 
Medicaid, and those enrolled in health maintenance organizations (HMOs) during the study period. 
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Patients were followed from the index date till the oral anticoagulant (OAC) prescription 
discontinuation date, switch to another class of OAC drug other than the index drug class, death, 
loss of continuous enrollment or end of the study period (December 31, 2016), whichever occurred 
first. Fill dates and days supplied per prescription were used to determine patients’ treatment 
episodes, defined as the period from the first fill date to the date when there were no residual days 
of supply. Patients were considered as continuing on the treatment as long as they had another 
medication fill of the same drug class within 45 days of the end of the last treatment 
episode.100,104,120,121 
OUTCOME MEASURES 
Clinical outcomes associated with NOAC or warfarin therapy were measured from the index date 
of NOAC or warfarin therapy till the oral anticoagulant (OAC) prescription discontinuation date, 
switch to another class of OAC drug other than the index drug class, death, loss of continuous 
enrollment or end of the study period (December 31, 2016), whichever occurred first.  Primary 
outcomes were classified as effectiveness and safety outcomes. Effectiveness outcomes included 
thromboembolic episodes – stroke or systemic embolism (SE), and myocardial infarction (MI). 
Safety outcomes included major bleeding episodes - gastrointestinal bleeding (MGB), intracranial 
bleeding (ICH), and major bleeding from other sites (OB). Composite effectiveness and composite 
safety outcomes comprising of occurrence of any of the effectiveness or safety outcomes, 
respectively, were also evaluated. Secondary outcome was a composite of stroke or systemic 
embolism (SE), myocardial infarction (MI), gastrointestinal bleeding, intracranial bleeding, 
bleeding from other sites, and all-cause mortality. In case a patient encountered multiple clinical 
outcomes, the occurrence of the first event was considered for the composite outcome measure. 
Outcomes were identified using the Medpar, Outpatient, and Carrier files in the Medicare data. 
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All-cause mortality (i.e. patients who died regardless of the reason for death) was identified based 
on the date of death information from the Medicare beneficiary summary file. 
COVARIATES` 
Pre-index period was used for assessment of patient demographics and clinical characteristics 
(clinical risk scores, comorbidities, and concomitant medication use). Comorbidities were 
evaluated using Charlson comorbidity index and chronic disease count. Chronic disease count was 
a simple total of all chronic conditions ever documented for a patient before the index date. This 
information was obtained using the Medicare Beneficiary Summary File – Chronic Condition 
Summary File. Baseline risk of stroke and major bleeding was assessed using the CHADS2, 
CHA2DS2-VASc, and HAS-BLED scores. CHA2DS2-VASc stroke risk score was based on 
CHADS2 and calculated as the summed total of the points determined for each diagnosis 
(congestive heart failure, hypertension, age>75 years, diabetes, and prior stroke or transient 
ischemic attack, or thromboembolism, vascular disease, aged 65-74 years, and sex). Modified 
HAS-BLED bleeding risk score was calculated based on evidence of hypertension, abnormal 
kidney or liver function, stroke, bleeding, age>65 years, and drugs/alcohol abuse or dependence. 
Labile International Normalized Ratio (INR) is a component of HAS-BLED score. However, since 
this information is not available in Medicare administrative claims data, modified HAS-BLED 
score with range 0 to 8 was calculated.31 Concurrent medication use was assessed based on paper 
by Kocis et al. which describes the extent to which patients with NVAF take chronic medications, 
other than anticoagulants, more frequently than once daily.122 
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STATISTICAL ANALYSIS 
Descriptive statistics were used to summarize the baseline characteristics of the study cohort. 
Frequencies and proportions were reported for categorical variables and means with standard 
deviations (SD) were reported for continuous variables.  
Patients initiating NOAC or warfarin therapy were expected to differ on baseline 
demographic and clinical characteristics and comorbidities. Since the treatment was main variable 
of interest, propensity score matching was used to create the final analysis cohort. Propensity 
scores were calculated for each patient using multivariable logistic regression. Each patient who 
initiated NOAC therapy was matched with a patient who initiated warfarin therapy using a greedy 
matching algorithm (i.e. the Mayo gmatch macro)123 based on the calculated propensity scores and 
the index date of the therapy. Patients were matched on a 1:1 basis using a caliper width of 0.05 
for the propensity score and time period of ±15 days for the index date. Standardized mean 
differences were used to assess the balance of the measured covariates and a difference of less than 
10% was used to indicate clinically irrelevant difference in the measured variables between the 
matched groups.124,125 Since the propensity score matching algorithm picks out the nearest 
available match based on the caliper width, patients who initiated NOAC therapy could still differ 
on baseline characteristics from patients who initiated warfarin therapy. These group differences 
were calculated using standardized differences in the total and the matched sample (Table 1).   
The time to each outcome of interest for the propensity-score-matched NOAC and warfarin 
treatment cohort was compared using Kaplan–Meier survival curves and tested for differences 
using log-rank tests. Incidence rates of stroke or SE, MI, and major bleeding episodes in the 
propensity score-matched cohort were calculated as the number of stroke/SE, MI, and major 
bleeding events per 100-person years. Stratified Cox proportional hazards regression were used to 
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compare outcomes in the propensity score-matched cohort, with STRATA statement in PROC 
PHREG procedure to account for the clustering within matched groups. Proportional hazards 
assumption was tested and found valid for all outcomes.126 All statistical analyses were performed 
using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
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Abstract: 
Objective: To compare the relative effectiveness and safety of non-vitamin K antagonists oral 
anticoagulants (NOACs) versus warfarin in elderly Medicare beneficiaries with NVAF and 
diabetes mellitus (DM). 
Methods: A retrospective cohort study using 2014 - 2016 5% national Medicare data was 
undertaken. NVAF patients with DM aged ≥65 years having at least one prescription for NOACs 
(dabigatran, rivaroxaban, apixaban, and edoxaban) or warfarin between July, 2014 and December, 
2015 were selected from the database. Date of first NOAC or warfarin prescription was defined as 
the index date. Patients initiating NOACs were 1:1 matched to warfarin patients on propensity 
score and index date. Stratified Cox proportional hazards models were used to estimate the clinical 
outcomes among patients initiating NOAC therapy versus warfarin therapy in the matched cohort. 
Results: The matched sample consisted of 4578 patients (2291 in each group). NOACs were found 
to significantly reduce the risk of stroke/SE compared to warfarin (Hazard Ratio (HR): 0.373, 95% 
confidence interval (CI): 0.247 - 0.564, p<0.001); but, no significant difference was seen between 
NOACs and warfarin in terms of reducing the risk of MI (HR: 0.864, CI: 0.594 – 1.257, p=0.446). 
NOACs were found to significantly reduce the risk of ICH (HR: 0.500, CI: 0.300 – 0.834, p=0.008) 
and OB (HR: 0.608, CI: 0.424 – 0.870, p=0.007); but no difference was seen in the risk of MGB 
(HR: 0.862, CI: 0.640 – 1.160, p=0.326) between NOACs and warfarin. NOACs were also found 
to reduce the risk of all-cause mortality (HR: 0.783, CI:0.656 – 0.873, p=0.007). The composite 
of effectiveness and safety outcomes, and all-cause mortality was statistically significant proving 
superior overall effectiveness and safety of NOAC therapy to warfarin therapy in terms of risk 
reduction (HR:0.685, CI:0.587 – 0.801, p<0.001).  
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Conclusion: Oral anticoagulation therapy with NOACs was found to be more effective than 
warfarin therapy. Results of this study may assist in clinical decision-making about anticoagulation 
therapies used in elderly NVAF patients with DM.  
Keywords: warfarin, stroke, novel oral anticoagulants, atrial fibrillation, diabetes 
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INTRODUCTION 
Atrial fibrillation (AF) is the most common heart rhythm disorder in the United States [1]. The 
annual prevalence of AF in the US population was estimated at 5.2 million in 2010 and projected 
to increase to 12.1 million by 2030, corresponding to an annual growth rate of 4.3 percent [2]. 
Advancing age is the most prominent risk factor for AF with a 1-in-4 lifetime risk after age 40 
years [3,4].  The Framingham study reported a five-fold increase in the risk of stroke with 
advancing age in AF patients [5], while the Scottish Renfrew/Paisley study with a 20-year follow-
up found a three-fold increase in the risk of stroke among AF patients [6].  Diabetes is another 
independent risk factor of AF with a prevalence of ranging from 24 – 30 percent among AF patients 
[7,8]. The relationship between diabetes mellitus and AF is mutual and reciprocal. Incidence of 
AF in patients with diabetes has been reported around 14.9% [9].  An observational study assessing 
the impact of diabetes mellitus (DM) on AF reported that over a mean follow-up of 7.2 ± 2.8 years, 
diabetic patients without AF at baseline had an age- and sex-adjusted incidence rate of AF 9.1 per 
1,000 person-years (95% CI: 8.6–9.7) compared with a rate of 6.6 (95% CI: 6.2–7.1) among 
nondiabetic patients [10]. Among diabetes patients, AF was independently associated with a 61 
percent greater risk for vascular death and all-cause mortality and higher risks for cardiovascular 
death and heart failure when compared with patients without AF [11]. 
Since 1950s, vitamin K antagonists (VKA) such as warfarin and low molecular weight 
heparins (LMWH) were used for anticoagulation treatment in AF patients. A meta-analysis of 
thromboembolic and bleeding outcomes by Hart et al. comparing warfarin to antiplatelet drugs in 
AF patients found warfarin to reduce the risk of stroke by 60 percent [12]. Bleeding is the most 
common side effect of warfarin and occurs in up to 41 percent of patients treated with warfarin. 
Additionally, its use can be cumbersome because of its food and drug interactions, dose 
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adjustment, and need for constant monitoring through laboratory testing [12,13]. Literature reports 
VKA therapy discontinuation rates of nearly 30-60 percent among patients with AF, and patients 
who discontinued therapy had significantly poor anticoagulation control in terms of poor  
International Normalized Ratio (INR), lesser Time in Therapeutic Range (TTR), and resultant 
underanticoagulation [14–16].  Beginning 2010, a new class of oral anticoagulants, non-vitamin 
K antagonists oral anticoagulants (NOACs) were introduced in the US market. Between 2010 and 
2015, the US Food and Drug Administration (FDA) approved four NOACs – dabigatran, apixaban, 
rivaroxaban and edoxaban – indicated for thromboprophylaxis in patients with non-valvular AF 
(NVAF). Of these, dabigatran is a direct thrombin inhibitor while others are factor Xa inhibitors. 
Direct targeting of factor Xa and thrombin provides a faster onset of action compared to warfarin, 
predictable pharmacokinetics and pharmacodynamics with a lesser potential for food and drug 
interactions allows for better fixed dosing schedules without dietary restrictions or routine 
coagulation monitoring [13]. 
Several randomized clinical trials (RCTs) have demonstrated that NOACs have at least 
equivalent efficacy and safety as compared to warfarin in terms of stroke/systemic embolism (SE) 
reduction and major hemorrhage rates, in patients with NVAF [17–20]. Results of phase III RCTs 
conducted in a sub-group of NVAF patients with diabetes report that NOACs have superior 
efficacy compared to warfarin. However, the safety profile of NOACs present a complex scenario. 
Bleeding events of NOACs were found to vary by a specific NOAC and dosage. While high dose 
edoxaban (60 mg) [20], as compared to low dose edoxaban (30 mg) and warfarin, reduced major 
bleeding in both NVAF patients with and without diabetes, apixaban [21] reduced major bleeding 
only among nondiabetic patients with NVAF, with no significant interaction by diabetes status. 
Interestingly, in patients with diabetes and NVAF, dabigatran and rivaroxaban were not 
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significantly different from warfarin in reducing the risk of major bleeding, and there was no 
significant interaction by diabetes status [22,23]. 
Proven efficacy and safety in RCTs, and the pharmacological characteristics of NOACs 
contribute to their practical advantages over traditional VKA therapy in reducing thromboembolic 
risk [13]. With widespread adoption of NOACs in the routine practice, several observational 
studies have been conducted to assess real world effectiveness and safety of these drugs [24–31]. 
These studies report a comparable or superior performance of NOACs to warfarin in stroke/SE 
reduction in patients with AF, but a variation in bleeding outcomes. Apixaban was found to have 
the lowest bleeding risk as compared to warfarin followed by dabigatran and rivaroxaban. 
Rivaroxaban was associated with higher bleeding risk as compared to warfarin, especially in 
elderly population [32–34]. 
While research has been conducted in the geriatric population with AF and diabetic patients 
with NVAF, no real world evidence is available in comparing the effectiveness and safety of 
NOAC therapy with warfarin in elderly NVAF patients with comorbid diabetes [35]. NVAF 
patients with DM are at an increased risk of thromboembolic and bleeding events due to the 
synergistic effect of DM and aging. Given the complex clinical interactions between AF and 
diabetes, care for elderly NVAF patients with DM can be complicated. Evidence obtained through 
this observational study may assist in clinical decision-making pertaining to the choice of oral 
anticoagulation therapy in patients with simultaneous presence of both AF and DM [35,36]. This 
study seeks to assess the comparative effectiveness and safety of NOAC therapy versus traditional 
warfarin therapy in elderly NVAF patients with concomitant diabetes mellitus using 5% national 
Medicare data. 
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METHODS 
Data Source  
A retrospective cohort study was conducted using the 2014-2016 5% national Medicare 
administrative claims data from the Centers of Medicare and Medicaid Services (CMS). Medicare 
is the federal health insurance program for those aged ≥65 years, people with disabilities, and 
people with end-stage renal disease in the United States, with an estimated 38 million fee-for-
service beneficiaries [37]. Medicare administrative claims include information on hospital 
inpatient, outpatient, Medicare carrier, Part D, skilled nursing facility, home health agency, and 
durable medical equipment claims. The medical claims are coded using International 
Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) and 10th Revision 
(ICD-10-CM), Current Procedural Terminology, or Healthcare Common Procedure Coding 
System codes. Pharmacy claims include information on drugs dispensed using the National Drug 
Code coding system.  
Study Population 
Elderly patients aged ≥65 years with NVAF and diabetes mellitus having at least one pharmacy 
claim for a NOAC (dabigatran, rivaroxaban, apixaban or edoxaban) or warfarin between July 1, 
2014 to December 31, 2015 were selected. Index date was defined as the date of first new 
prescription claim for a NOAC or warfarin between July 1, 2014 to December 31, 2015. To ensure 
the inclusion of only treatment-naïve NOAC and warfarin users, a rolling pre-index period of six 
months was used to confirm that the patients did not have a prior exposure to NOACs or warfarin. 
The time period from index date to December 31, 2016 was used for identification of outcomes; 
thus, ensuring that each patient had at least 12 months of follow-up period.  
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Patients were required to have continuous medical (Part A and Part B) and pharmacy (Part 
D) enrolment for six months prior to the index date. In Medicare data, beneficiary Part A and Part 
B enrollment information is available as single variables showing number of months a beneficiary 
was enrolled in Medicare Part A and Part B in a given calendar year. Since, a rolling pre-index 
period was used, patients having pre-index period spread across 2014 and 2015 were required to 
have at least three months of Part A and Part B continuous enrollment in each calendar year. 
Patients were required to have one or more inpatient or outpatient claims carrying a diagnosis code 
for NVAF (ICD-9-CM code 427.31 and ICD-10-CM code I48.0, I48.1, I48.2, I48.91) [38] and 
have at least two outpatient claims or at least one inpatient claim for diabetes (ICD-9-CM code 
250.* and ICD-10-CM code E11.*) within the six-month pre-index period [39].  
Patients with evidence of valvular heart disease, heart valve replacement or surgery, venous 
thromboembolism (VTE), pulmonary embolism, transient AF (pericarditis, hyperthyroidism, 
thyrotoxicity), and end-stage renal disease in the pre-index period were excluded from the 
study.[30,31] Patients who underwent hip or knee replacement surgery within six weeks prior to 
the index date were excluded. This study also excluded beneficiaries with dual eligibility for 
Medicare and Medicaid, and those enrolled in health maintenance organizations (HMOs) during 
the study period. 
Patients were followed from the index date till the oral anticoagulant (OAC) prescription 
discontinuation date, switch to another class of OAC drug other than the index drug class, death, 
loss of continuous enrollment or end of the study period (December 31, 2016), whichever occurred 
first. Fill dates and days supplied per prescription were used to determine patients’ treatment 
episodes, defined as the period from the first fill date to the date when there were no residual days 
of supply. Patients were considered as continuing on the treatment as long as they had another 
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medication fill of the same drug class within 45 days of the end of the last treatment episode [40–
43]. 
Outcome Measures 
Clinical outcomes associated with NOAC or warfarin therapy were measured from the index date 
of NOAC or warfarin therapy till the oral anticoagulant (OAC) prescription discontinuation date, 
switch to another class of OAC drug other than the index drug class, death, loss of continuous 
enrollment or end of the study period (December 31, 2016), whichever occurred first.  Primary 
outcomes were classified as effectiveness and safety outcomes. Effectiveness outcomes included 
thromboembolic episodes – stroke or systemic embolism (SE), and myocardial infarction (MI). 
Safety outcomes included major bleeding episodes - gastrointestinal bleeding (MGB), intracranial 
bleeding (ICH), and major bleeding from other sites (OB). Composite effectiveness and composite 
safety outcomes comprising of occurrence of any of the effectiveness or safety outcomes, 
respectively, were also evaluated. Secondary outcome was a composite of stroke or systemic 
embolism (SE), myocardial infarction (MI), gastrointestinal bleeding, intracranial bleeding, 
bleeding from other sites, and all-cause mortality. In case a patient encountered multiple clinical 
outcomes, the occurrence of the first event was considered for the composite outcome measure. 
Outcomes were identified using the Medpar, Outpatient, and Carrier files in the Medicare data. 
All-cause mortality (i.e. patients who died regardless of the reason for death) was identified based 
on the date of death information from the Medicare beneficiary summary file. 
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Covariates 
Pre-index period was used for assessment of patient demographics and clinical characteristics 
(clinical risk scores, comorbidities, and concomitant medication use). Comorbidities were 
evaluated using Charlson comorbidity index and chronic disease count. Chronic disease count was 
a simple total of all chronic conditions ever documented for a patient before the index date. This 
information was obtained using the Medicare Beneficiary Summary File – Chronic Condition 
Summary File. Baseline risk of stroke and major bleeding was assessed using the modified 
CHADS2, CHA2DS2-VASc, and HAS-BLED scores. Since the study population consists of NVAF 
patients with diabetes, diabetes was excluded as a risk factor in calculating CHADS2 and 
CHA2DS2-VASc risk scores. CHA2DS2-VASc stroke risk score was based on CHADS2 and 
calculated as the summed total of the points determined for each diagnosis (congestive heart 
failure, hypertension, aged >75 years, prior stroke or transient ischemic attack, or 
thromboembolism, vascular disease, aged 65-74 years, and sex). Modified HAS-BLED bleeding 
risk score was calculated based on evidence of hypertension, abnormal kidney or liver function, 
stroke, bleeding, age >65 years, and drugs/alcohol abuse or dependence. Labile International 
Normalized Ratio (INR) is a component of HAS-BLED score. However, since this information is 
not available in Medicare administrative claims data, modified HAS-BLED score with range 0 to 
8 was calculated [31]. Concurrent medication use was assessed based on paper by Kocis et al. 
which describes the extent to which patients with NVAF take chronic medications, other than 
anticoagulants, more frequently than once daily [44]. 
44 
 
Statistical Analysis 
Descriptive statistics were used to summarize the baseline characteristics of the study cohort. 
Frequencies and proportions were reported for categorical variables and means with standard 
deviations (SD) were reported for continuous variables.  
Patients initiating NOAC or warfarin therapy were expected to differ on baseline 
demographic and clinical characteristics and comorbidities. Since the treatment was main variable 
of interest, propensity score matching was used to create the final analysis cohort. Propensity 
scores were calculated for each patient using multivariable logistic regression. Each patient who 
initiated NOAC therapy was matched with a patient who initiated warfarin therapy using a greedy 
matching algorithm (i.e. the Mayo gmatch macro) [45] based on the calculated propensity scores 
and the index date of the therapy. Patients were matched on a 1:1 basis using a caliper width of 
0.05 for the propensity score and time period of ±15 days for the index date. Standardized mean 
differences were used to assess the balance of the measured covariates and a difference of less than 
10% was used to indicate clinically irrelevant difference in the measured variables between the 
matched groups [46,47]. Since the propensity score matching algorithm picks out the nearest 
available match based on the caliper width, patients who initiated NOAC therapy could still differ 
on baseline characteristics from patients who initiated warfarin therapy. These group differences 
were calculated using standardized differences in the total and the matched sample (Table 1).   
The time to each outcome of interest for the propensity-score-matched NOAC and warfarin 
treatment cohort was compared using Kaplan–Meier survival curves and tested for differences 
using log-rank tests. Incidence rates of stroke or SE, MI, and major bleeding episodes in the 
propensity score-matched cohort were calculated as the number of stroke/SE, MI, and major 
bleeding events per 100-person years. Stratified Cox proportional hazards regression were used to 
compare outcomes in the propensity score-matched cohort, with STRATA statement in PROC 
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PHREG procedure to account for the clustering within matched groups. Proportional hazards 
assumption was tested and found valid for all outcomes [48]. All statistical analyses were 
performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA). 
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RESULTS 
Of 5,833 eligible patients with NVAF and diabetes before propensity score matching, 2,509 
patients (43.01%) were initiated on warfarin therapy and 3,324 patients (56.99%) initiated on 
NOAC therapy between July 1, 2014 and December 31, 2015. Demographic and clinical 
characteristics of treatment groups before matching are outlined in Table 1a. Patients initiating 
warfarin therapy were more likely to have history of prior bleeding (21.96% vs. 16.94%, p<0.001), 
congestive heart failure (65.80% vs. 57.19%, p<0.001), myocardial infarction (10.20% vs. 7.49%, 
p<0.001), coronary artery disease (46.99% vs. 43.74%, p=0.014), and renal disease (60.46% vs. 
50.06%, p<0.001). However, no significant difference was seen between two treatment groups in 
the history of stroke (15.46% vs. 14.89%, p=0.546). Mean follow-up time for patients initiating 
NOAC and warfarin therapy was 12.07±8.23 months and 10.11±7.74 months respectively.  
After 1:1 propensity score matching, 2291 warfarin-NOAC matched pairs were obtained. 
Demographic and clinical characteristics of the matched treatment groups are outlined in Table 
1b. Comparison of treatment groups after propensity score matching on baseline demographic and 
clinical characteristics did not show significant differences (standardized difference >10%). Figure 
1 depicts the distribution of the propensity scores before and after matching. Before matching, the 
distribution of the propensity scores was different between the NOAC and warfarin treatment 
groups, which indicates that the groups differed significantly in baseline demographics and 
comorbidities. The graphs overlap almost perfectly in the matched sample indicating that the two 
groups have a similar distribution of propensity scores. All further analyses were carried out on 
the propensity-score matched sample. 
An evaluation of long-term effectiveness and safety outcomes revealed that a significantly 
higher proportion of patients initiating warfarin therapy experienced stroke/SE (4.23% vs. 2.44%, 
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p<0.001) and composite outcome (23.13% vs. 20.12%, p=0.013) as compared to patients who 
initiated NOAC therapy. Although a greater proportion of patients who initiated warfarin therapy 
experienced ICH (2.62% vs. 1.79%, p=0.056), OB (4.41% vs. 3.32%, p=0.055), and death (11.17% 
vs. 10.08%, p=0.231), these differences were not statistically significant. No differences were seen 
in the proportion of patients experiencing MI (3.58% vs. 3.36%, p=0.686) and MGB (5.33% vs. 
5.63%, p=0.649).  
Table 1a. Baseline demographic and clinical characteristics of the study before propensity 
score matching 
Variable 
Warfarin users 
(N= 2509) 
NOAC users 
(N= 3324) 
Absolute 
Standardized 
difference  
N /Mean % / SD N /Mean % / SD 
 
Age, years 77.15 7.22 77 7.29     0.196 
Age, years      
65 - 74 990 39.46 1382 41.58 0.050 
75 - 84 1072 42.73 1342 40.37  
85 and above 447 17.82 600 18.05   
     
Gender     0.045 
Female 1131 45.08 1526 45.91  
Male 1378 54.92 1798 54.09   
     
Race     0.043 
White 2326 92.71 3086 92.84  
Non-white 183 7.29 238 7.16   
     
US geographic region     0.186 
Northeast 620 24.71 720  21.66  
North Central 682 27.18 733 22.05  
West 350 13.95 449 13.51  
South 857 34.16 1422 42.78   
     
Baseline clinical 
characteristics 
     
Charlson Comorbidity Index 
score 
3.07 2.95 2.54 2.79 0.184 
Chronic Disease Count Score 9.00 2.91 8.56 2.98 0.149 
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Modified CHA2DS2-VASc 
score 
5.23 1.34 5.10 1.37 0.108 
CHADS2 score 3.57 1.07 3.45 1.10 0.111 
Modified HAS-BLED score 3.30 1.01 3.14 0.99 0.157  
     
Medical history      
Prior bleeding 551 21.96 563 16.94 0.127 
Prior stroke 388 15.46 495 14.89 0.016 
Prior systemic embolism 55 2.19 32 0.96 0.099 
Congestive heart failure 1651 65.80 1901 57.19 0.178 
Hypertension 2481 98.88 3266 98.26 0.053 
Renal disease 1517 60.46 1664 50.06 0.210 
Myocardial infarction 256 10.20 249 7.49 0.096 
Coronary artery disease 1179 46.99 1454 43.74 0.065 
Transient ischemic attack 184 7.33 269 8.09 0.028 
Peripheral vascular disease 503 20.05 597 17.96 0.053 
Abnormal liver function 178 7.09 187 5.63 0.060  
     
Baseline medication use      
Angiotensin converting 
enzyme (ACE) inhibitors 
903 35.99 1212 36.46 0.010 
Diuretics 1318 52.53 1630 49.04 0.070 
Statins 1676 66.80 2209 66.46 0.007 
Beta blockers 1830 72.94 2454 73.83 0.020 
Calcium channel blockers 893 35.59 1185 35.65 0.001 
H2 receptor antagonists 177 7.05 204 6.14 0.037 
Proton pump inhibitors 833 33.20 1059 31.86 0.029 
Anti-platelet agents 438 17.46 602 18.11 0.017 
NSAIDs 206 8.21 347 10.44 0.077 
Anti-arrhythmic agents 908 36.19 1239 37.27 0.023 
Anti-anginal agents 445 17.74 425 12.79 0.134 
Antidiabetic agents 1444 57.55 1896 57.04 0.010 
Opioids 901 35.91 1143 34.39 0.032 
Antidepressants 630 25.11 834 25.09 0.004 
Benzodiazepines 235 9.37 312 9.39 0.006 
Potassium supplements 582 23.20 690 20.76 0.060 
Thyroid hormonal drugs 543 21.64 789 23.74 0.050 
Anti-gout drugs 218 8.69 218 6.56 0.080 
Anti-adrenal agents 461 18.37 591 17.78 0.015 
NOACs, Non-vitamin K antagonists oral anticoagulants; SD, Standard Deviation 
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Table 1b. Baseline demographic and clinical characteristics of the study after propensity 
score matching 
Variable 
Warfarin users 
(N= 2291) 
NOAC users 
(N= 2291) 
Absolute 
Standardized 
difference  
N /Mean % / SD N /Mean % / SD 
 
Age, years 77.15 7.22 77.20 7.25 0.008 
Age, years 
    
0.016 
65 - 74 909 39.68 926 40.42 
 
75 - 84 974 42.51 941 41.07 
 
85 and above 408 17.81 424 18.51 
 
      
Gender 
    
0.015 
Female 1051 45.88 1036 45.22 
 
Male 1240 54.12 1255 54.78 
 
      
Race 
    
0.015 
White 2131 93.02 2130 92.97 
 
Non-white 160 6.98 161 7.03 
 
      
US geographic region     0.034 
Northeast 554 24.18 559 24.40 
 
North Central 601 26.23 568 24.79 
 
West 313 13.66 317 13.84 
 
South 823 35.92 847 36.97 
 
 
    
 
Baseline clinical 
characteristics 
     
Charlson Comorbidity Index 
score 
2.98 2.91 2.74 2.86 0.045 
Chronic Disease Count Score 8.91 2.93 8.86 2.93 0.016 
Modified CHA2DS2-VASc 
score 
5.23 1.34 5.18 1.37 0.025 
CHADS2 score 3.55 1.08 3.53 1.09 0.017 
Modified HAS-BLED score 3.26 1.01 3.23 0.98 0.035  
    
 
Medical history 
     
Prior bleeding 474 20.69 447 19.51 0.029 
Prior stroke 348 15.19 343 14.97 0.006 
Prior systemic embolism 36 1.57 26 1.13 0.038 
Congestive heart failure 1456 63.55 1450 63.29 0.005 
Hypertension 2263 98.78 2262 98.73 0.004 
Renal disease 1331 58.10 1302 56.83 0.025 
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Myocardial infarction 221 9.65 197 8.60 0.036 
Coronary artery disease 1066 46.53 1050 45.83 0.014 
Transient ischemic attack 174 7.59 163 7.11 0.018 
Peripheral vascular disease 450 19.64 444 19.38 0.007 
Abnormal liver function 155 6.77 146 6.37 0.016       
Baseline medication use      
Angiotensin converting 
enzyme (ACE) inhibitors 841 36.71 827 36.10 0.013 
Diuretics 1170 51.07 1182 51.59 0.010 
Statins 1531 66.83 1540 67.22 0.008 
Beta blockers 1680 73.33 1673 73.02 0.007 
Calcium channel blockers 825 36.01 824 35.97 0.001 
H2 receptor antagonists 157 6.85 159 6.94 0.003 
Proton pump inhibitors 752 32.82 769 33.57 0.016 
Anti-platelet agents 413 18.03 396 17.29 0.019 
NSAIDs 199 8.69 208 9.08 0.014 
Anti-arrhythmic agents 824 35.97 862 37.63 0.034 
Anti-anginal agents 375 16.37 343 14.97 0.038 
Antidiabetic agents 1310 57.18 1306 57.01 0.003 
Opioids 815 35.57 796 34.74 0.017 
Antidepressants 562 24.53 599 26.15 0.037 
Benzodiazepines 219 9.56 224 9.78 0.007 
Potassium supplements 509 22.22 494 21.56 0.016 
Thyroid hormonal drugs 495 21.61 550 24.01 0.057 
Anti-gout drugs 194 8.47 149 6.50 0.005 
Anti-adrenal agents 414 18.07 413 18.03 0.001 
 NOACs, Non-vitamin K antagonists oral anticoagulants; SD, Standard Deviation  
Incidence rates of clinical outcomes are presented in Table 2 and Table 3. As compared to 
patients initiating warfarin therapy, patients initiating NOAC therapy were found to have 
significantly lower incidence of stroke/SE as compared to warfarin (2.322 per 100 person-years 
vs. 4.776 per 100 person-years, p<0.001), ICH (2.909 vs. 1.685, p=0.008), OB (4.966 vs. 3.162, 
p=0.003), and all-cause mortality (12.330 vs. 9.451, =0.004). No significant differences were 
observed in the incidence rates of MI (4.003 vs. 3.186, p=0.383) and MGB (5.991 vs. 5.385, 
p=0.916) between patients initiating NOACs versus patients initiating warfarin.  
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Table 2. Hazard ratio of effectiveness outcomes in propensity-score matched cohort 
Outcome Incidence rate per 
100 person-years 
Hazard ratio (95% 
confidence intervals) 
p value 
 
Warfarin NOACs 
  
Stroke/SE 4.776 2.322 0.373 (0.247 - 0.564) <0.001 
Myocardial infarction 4.003 3.186 0.864 (0.594 - 1.257) 0.446 
Composite effectiveness 
outcomea 
8.481 5.279 0.567 (0.428 - 0.757) <0.001 
a A composite of stroke, systemic embolism (SE), and myocardial infarction (MI) 
 
Table 3. Hazard ratio of safety outcomes in propensity-score matched cohort 
Outcome 
Incidence rate per 
100 person-years 
Hazard ratio (95% 
confidence intervals) 
p value 
 Warfarin NOACs   
Major Bleeding     
Intracranial 2.909 1.685 0.500 (0.300 – 0.834) 0.008 
Gastrointestinal 5.991 5.385 0.862 (0.640 – 1.160) 0.326 
Other 4.966 3.162 0.608 (0.424 – 0.870) 0.007 
Composite safety 
outcomea 
12.786 9.669 0.701 (0.563 - 0.873) 0.002 
     
All-cause mortality 12.330 9.451 0.783 (0.656 – 0.935) 0.007 
Composite outcomeb 27.444 19.999 0.685 (0.587 - 0.801) <0.001 
aA composite of ICH, MGB, and OB 
bA composite of stroke, systemic embolism (SE), myocardial infarction (MI), gastrointestinal 
bleeding (MGB), intracranial bleeding (ICH), bleeding from other sites (OB), and all-cause 
mortality 
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Figure 1.  Distribution of propensity scores before and after matching for NOAC and 
warfarin therapy among Medicare beneficiaries matched on propensity score and date of 
surgery 
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Figure 2. Kaplan-Meier survival curves for NOAC and warfarin therapy among Medicare 
beneficiaries with NVAF and DM 
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Hazard ratios for effectiveness outcomes are presented in Table 2. Refer Figure 2 for 
Kaplan Meier (KM) plots of effectiveness and safety outcomes. Survival curves for occurrence of 
stroke/SE were significantly different for NOAC patients and warfarin patients as evident from 
significant log-rank test (p<0.001); however, the survival curves for MI with two therapies seemed 
to overlap (p=0.215). NOACs were found to significantly reduce the risk of stroke/SE compared 
to warfarin (Hazard Ratio (HR): 0.373, 95% confidence interval (CI): 0.247 - 0.564, p<0.001); 
but, no significant difference was seen between NOACs and warfarin in terms of reducing the risk 
of myocardial infarction (HR: 0.864, CI: 0.594 – 1.257, p=0.446). Overall, effectiveness of 
NOACs was found to be superior compared to warfarin as measured using the composite 
effectiveness outcome comprising of occurrence of either stroke/SE or MI. Superiority was seen 
in both – risk reduction of stroke/SE or MI (HR: 0.629, CI: 0.457 – 0.866) and longer survival 
time for these outcomes (p<0.001).  
Hazard ratios for safety outcomes are presented in Table 3. NOACs were found to 
significantly reduce the risk of ICH (HR: 0.500, CI: 0.300 – 0.834, p=0.008) and bleeding from 
other sites (HR: 0.608, CI: 0.424 – 0.870, p=0.007) and prolong the occurrence as seen from 
significantly different survival curves for ICH (p=0.006) and OB (p=0.008). However, the survival 
curves for MGB almost overlapped (p=0.562) and no difference was seen in the risk of MGB (HR: 
0.862, CI: 0.640 – 1.160, p=0.326) between NOACs and warfarin. The composite safety outcome 
of major bleeding events (occurrence of any of the three safety outcomes) was significant 
(HR:0.701, CI:0.563 – 0.935, p=0.002). NOACs were also found to reduce the risk of all-cause 
mortality (HR: 0.783, CI:0.656 – 0.873, p=0.007) and increase overall survival (p<0.001). The 
composite of effectiveness and safety outcomes, and all-cause mortality was statistically 
significant proving superior overall effectiveness and safety of NOAC therapy to warfarin therapy 
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in terms of risk reduction (HR:0.685, CI:0.587 – 0.801, p<0.001) and prolongation of survival 
(p<0.001). 
DISCUSSION 
Given their practical advantages over traditional warfarin therapy, NOACs have become first 
choice of oral anticoagulation therapy in patients with NVAF. However, patients with DM 
constitute a unique subgroup among NVAF patients, having a significantly higher risk of both 
thromboembolic episodes and hemorrhagic events. Given the diabetes-related propensity for both 
thromboembolic and hemorrhagic events, the issue of whether NOACs maintain their better 
efficacy and safety profile as compared to warfarin in the high-risk setting of diabetic patients is 
clinically relevant. Further, care of elderly NVAF patients with concomitant diabetes presents a 
highly vulnerable segment of population which demands special consideration with respect to oral 
anticoagulation therapy. While several observational studies have been conducted to assess 
comparative effectiveness and safety of NOACs versus warfarin in elderly NVAF population, ours 
is the first study to evaluate the effectiveness and safety of NOACs compared to warfarin in elderly 
NVAF population with DM. In this study, we compared the risk of thromboembolic episodes and 
hemorrhagic events in elderly NVAF patients with concomitant DM using the 5% national 
Medicare sample from 2014-2016. Propensity score matching was used to control for baseline 
patient demographic and clinical characteristics. 
Our study found a greater incidence rate of stroke/SE, ICH, OB, and all-cause mortality 
among patients on warfarin therapy compared to patients using NOACs. We believe a greater 
incidence of clinical outcomes was observed given the baseline demographic composition and 
clinical characteristics of our study population which represents a high-risk and vulnerable group 
of patients with AF. High risk of stroke in our study population is evident through higher 
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CHA2DS2-VASc scores (mean modified CHA2DS2-VASc~5) after adjusting for diabetes status in 
both treatment groups. A significant proportion of study population had a history of prior stroke 
and prior bleeding.  Prior stroke has been known to increase the risk of recurrent ischemic attack 
and major hemorrhage which might explain higher incidence of stroke/SE and bleeding events in 
our study [49,50].  Additionally, a substantial portion of patients in our study were on several 
concomitant medication which might increase the risk of hemorrhage [51]. NVAF patients in our 
study had a substantial comorbidity burden as evident from the baseline clinical characteristics. 
Overall higher incidence of clinical outcomes and all-cause mortality may also be associated to 
general presence multiple comorbidities along with NVAF and diabetes in this population. 
Using Cox proportional hazards models, the results of the current study showed that 
compared to warfarin, NOACs were found to significantly lower the risk of stroke/SE, intracranial 
bleeding, bleeding from other sites, and all-cause mortality in elderly patients with NVAF and DM 
treated in routine clinical practice.  Differences in the risk reduction associated with NOAC and 
warfarin therapies may be influenced by differences in pathophysiology of NVAF and DM and 
pharmacological action of two drug classes. Pathophysiology of NVAF with concomitant DM is 
different from NVAF alone due to complex interaction in molecular mechanisms between NVAF 
and DM [36]. Variability of glycemic control in diabetic patients may affect the pharmacokinetics 
and anticoagulant activity of warfarin [52]. Additionally, the anticoagulant activity of warfarin is  
expressed through non-specific mechanism of action which affects several proteins outside the 
coagulation system, in turn, increasing the risk of cardiovascular and hemorrhagic events [53]. 
These factors may explain increased risk of hemorrhagic events associated with warfarin in 
comparison to NOACs.  
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Findings of this study are in agreement with the results of 4 large phase III clinical trials of 
NOACs - (apixaban in ARISTOTLE [17], dabigatran in RE‐LY[18], rivaroxaban in ROCKET AF 
[19], and edoxaban in ENGAGE AF-TIMI 8 [54]) in which 23 - 40 percent of NVAF patients had 
diabetes at the baseline. In two meta‐analyses of these four clinical trials, NOACs, compared with 
warfarin, were found to reduce the rate of stroke/SE, ICH, and death. This effect was similar among 
AF patients with and without diabetes. Similarly, no difference was seen among NVAF patients 
with and without diabetes with respect to bleeding events, although the relative safety of NOACs 
was apparent more among patients without diabetes [55,56]. Similar pattern of results was 
observed in the meta-analysis by Patti et al. [57] which focused specifically on NVAF patients 
with concomitant diabetes from the above mentioned 4 phase III clinical trials. Patti et al. reported 
that despite patients with diabetes having higher rates of thromboembolic episodes and mortality 
and compared to patients without diabetes, similar efficacy of NOACs was observed in both 
patients with or without diabetes. The safety of NOACs however, presented a more complex 
scenario where rate of hemorrhagic events was found to depend on specific NOAC and its dose 
leading to conclusion that risk reduction in hemorrhagic events was higher in AF patients without 
diabetes as compared to AF patients with diabetes. Our study found NOACs to significantly reduce 
the risk of ICH and bleeding from other sites in elderly NVAF patients with diabetes. However, 
no differences were seen in rates of gastrointestinal bleeding between NOACs and warfarin. 
Comparability to results found by Patti et al. may be limited since we did not evaluate drug- or 
dose-specific effects of NOACs compared to warfarin. Additionally, our study focused only on 
NVAF patients with diabetes and hence, assessing comparative effectiveness and safety of NOACs 
over warfarin in patients without diabetes was not undertaken.  
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Since findings obtained in clinical trials may not always replicate in routine clinical 
practice, understanding real-world effectiveness and safety of NOACs versus warfarin in elderly 
NVAF population with diabetes is necessary. We found two observational studies evaluating 
effectiveness and safety of these drugs. The ARISTOPHANES Diabetes Subgroup Analysis 
study[58] used CMS Medicare data and data from four US commercial databases to evaluate 
relative effectiveness and safety of NOACs versus warfarin in NVAF patients with diabetes. The 
study reported apixaban and rivaroxaban to be associated with lower rates of stroke/SE, while 
apixaban and dabigatran had lower rates of MGB compared to warfarin demonstrating overall 
superiority of NOACs over warfarin. Coleman et al. assessed effectiveness and safety of 
rivaroxaban compared to warfarin in NVAF patients with diabetes using administrative claims 
data and found nonsignificant risk reductions in stroke/SE and major bleeding; thus, providing 
evidence of rivaroxaban’s non-inferior effectiveness and safety profile in this population [59]. 
Results of our study agree with the findings of these studies. Comparison of NOACs, as a drug 
class, to warfarin in this study provides evidence of better overall effectiveness and safety on 
NOACs compared to warfarin. 
The synergistic effect of aging and diabetes predisposes patients with NVAF to 
thromboembolic and hemorrhagic episodes. Diabetes is associated with numerous metabolic 
defects including insulin resistance, impaired glucose tolerance, proinflammatory mediators, 
abnormalities of hemostasis, fibrinolysis, and angiogenesis which could lead to precipitation of 
adverse cardiovascular events [60,61]. With the advent of NOACs with better pharmacological 
profile, warfarin is losing its status as the preferred therapy for thromboprophylaxis, especially in 
NVAF patients with DM [52,53]. As NOACs become a preferred therapy for oral 
thromboprophylaxis in NVAF patients [62], there is a need for more real-world evidence 
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supporting the effectiveness and safety profile of NOACs compared to warfarin in the high-risk 
group of elderly AF patients with concomitant diabetes. 
The current study has several strengths. First, this study used real world data on patients 
receiving care in actual clinical practice. The study results are therefore more generalizable 
compared to results of previous randomized clinical trials. Second, patients initiating NOAC or 
warfarin therapy were matched on baseline demographics and comorbidities using propensity 
scores. In addition, patients were also matched on the index date of the NOAC and warfarin 
prescription. The matching process reduces the likelihood of selection bias in observational studies 
ensuring that all baseline characteristics are balanced equally across treatment groups. Thirdly, 
effectiveness and safety of NOACs versus warfarin was assessed in a high-risk group of elderly 
patients over a broad set of clinical outcomes which better characterized the superiority of NOACs, 
as a drug class, over warfarin.  
Results of this study should be interpreted in the light of some limitations. Owing to sample 
size limitations, we evaluated effectiveness and safety of NOACs as a drug class instead of 
comparing individual NOAC to warfarin. It is possible that effectiveness or safety outcomes of 
individual NOACs may not exhibit similar results. Although, the treatment groups were matched 
using propensity scores, potential residual confounders still exist; e.g. over-the counter aspirin use 
and warfarin dose adjustment, which are not available in the dataset. Claims data lack laboratory 
data and accuracy in coding diagnoses. AF and DM were identified using ICD-9-CM and ICD-10-
CM codes, which is different from clinical trials. Additionally, the presence of a claim for a filled 
prescription does not indicate whether the medication was consumed or taken as prescribed. 
Compared with clinical trials, the follow-up period for the cohort in this study was also shorter, 
which may impact our results. Finally, although understanding the US Medicare population is 
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important in managing NVAF, findings from this elderly population may not be generalized to 
other populations.
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CHAPTER IV 
CONCLUSION 
NOACs and warfarin are common drugs of choice for thromboprophylaxis in patients with AF. 
The current study compared relative effectiveness and safety of NOACs versus warfarin in a broad 
set of clinical outcomes in real world patients after accounting for baseline differences between 
the two patient groups. Our study found that NOACs, as a class, reduced the risk of stroke/SE, 
intracranial bleeding, bleeding from other sites, and all-cause mortality in elderly NVAF patients 
with diabetes. No significant differences were seen in the risk of myocardial infarction and major 
gastrointestinal bleeding. Overall, NOACs appeared to be the superior oral anticoagulation 
strategy for elderly NVAF patients with diabetes. Evidence from this study can assist clinical 
decision-making about choice of thromboprophylaxis therapy in elderly NVAF patients with 
diabetes. However, individual patient factors should be taken into consideration in addition to 
clinical evidence while making clinical decisions about anticoagulation therapy.
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APPENDIX A: SUPPLEMENTAL TABLES 
Supplemental table 1. ICD-9-CM and ICD-10-CM codes for exclusion criteria 
Diagnosis 
ICD-9-CM Diagnosis or 
Procedural Codes 
ICD-10-CM Diagnosis or 
Procedural Codes 
Rheumatic mitral valvular 
heart disease, mitral valve 
stenosis 
394.0, 394.1, 394.2, 394.9, 
396.0, 396.1, 396.8, 396.9, 
424.0, 745.xx 
I05.0-I05.9, I06.0-I06.9, 
I34.0-I34.9, I35.0-I35.9 
Heart valve replacement or 
surgery 
V422, V433, 35.05-35.09, 
35.20-35.28, 35.97 
Z95.2, Z95.3, Z95.4 
Venous thromboembolism 451-453, 671.3, 671.4, 671.9, 
415.1, 673.2, 673.8 
I80.0-I80.3, I80.8, I80.9, 
I82.0-I82.9, I82.A, I82.B, 
I82.C 
Transient AF (Heart valve 
replacement / transplant, 
pericarditis, thyrotoxicity) 
Pericarditis: 006.8, 017.9, 
036.41, 074.21, 093.81, 098.83, 
115.93, 390, 391, 392.0, 393, 
411.0, 420.90, 420.91, 420.99, 
423.0, 423.1, 423.2, 423.8, 
423.9 
Thyrotoxicity: 242.0, 242.1, 
242.2, 242.3, 242.4, 242.8, 
242.9 
I30.0, I30.1, I30.8, I30.9, 
I31.0, I31.1, I31.2, I31.3, 
I31.4, I31.8, I31.9, I32 
Thyrotoxicity: E05.0-E05.9 
Knee replacement surgery V43.65 
CPT codes: 27445, 27446, 
27447, 27486, 27487 
Z96.65 
CPT codes: 27445, 27446, 
27447, 27486, 27487 
Hip replacement surgery  V43.64 
CPT codes: 27120, 27122, 
27125, 27130, 27132, 27134, 
27137, 27138 
Z96.64 
CPT codes: 27120, 27122, 
27125, 27130, 27132, 27134, 
27137, 27138 
 
Supplemental Table 2. ICD-9-CM and ICD-10-CM diagnosis codeads for clinical outcomes 
Diagnosis ICD-9-CM codes ICD-10-CM codes 
Stroke or Systemic Embolism 
 
Stroke 
430.xx - 432.xx, 433.x1, 
434.x1, 436 
I60.0-I60.9, I61.0-I61.9, 
I62.0-I62.9, I63.0-I63.9, I64.9 
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Systemic embolism 444.x, 445.x I74.0-I74.9 
Transient ischemic attack 435.x G45.0-G45.9* 
Major Bleeding  
Major intracranial 
hemorrhage (ICH) 
430, 431, 432.x, 852.x, 853.x I60, I61, I62.0, I62.1, I62.9 
Major gastrointestinal 
bleeding (MGB) 
456.0, 456.20, 530.21, 530.7, 
530.82, 531.0x, 531.2x, 
531.4x, 531.6x, 532.0x, 
532.2x, 532.4x, 532.6x, 
533.0x, 533.2x, 533.4x, 
533.6x, 534.0x, 534.2x, 
534.4x, 534.6x, 535.01, 
535.11, 535.21, 535.31, 
535.41, 535.51, 535.61, 
535.71, 537.83, 
537.84, 562.02, 562.03, 
562.12, 562.13, 568.81, 569.3, 
569.85, 578.x 
Procedure code: 44.43 
K92.0, K92.1, I85.0, I98.20, 
I98.3, K22.10, K22.12, 
K22.14, K22.16, K25.0, 
K25.2, K25.4, K25.6, K26.0, 
K26.2, K26.4, K26.6, K27.0, 
K27.2, K27.4, K27.6, K28.0, 
K28.2, K28.4, K28.6, K29.0, 
K63.80, K31.80, K55.20, 
K62.5, K92.2 
Major bleeding from other 
sites 
(OB) 
285.1, 360.43, 362.43, 362.81, 
363.61, 363.62, 363.72, 
364.41, 372.72, 374.81, 
376.32, 377.42, 379.23, 
423.0x, 596.7x, 599.7x, 
602.1x, 620.1, 621.4, 626.2, 
626.5, 626.7, 626.8, 626.9, 
719.1x, 782.7, 784.7, 784.8, 
786.3x, 958.2, 997.02, 998.11 
Procedure code: 99.04 
N02.0, N02.1, N02.2, 
N02.3,  N02.4, N02.5, N02.6, 
N02.7, N02.8, N02.9, K66.1, 
N93.8, N93.9, N95.0, R04.1, 
R04.2, R04.8, R04.9, R31.0, 
R31.1, R31.8, R58, D68.3, 
H35.6, H43.1, H45.0, M25.0 
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Supplemental Table 3. ICD-9-CM and ICD-10-CM codes for comorbidities 
Disorder/Disease ICD-9-CM codes ICD-10 codes 
Congenital heart disease 746.9 Q20-Q28 
Congestive heart failure 428.0 I50.0-I50.9, I11.0, I13.0, 
I13.2 
Hypertension 401.9 I10.0-I10.9, I11.0-I11.9, 
I12.0-I12.9, I13.0-I13.9, 
I15.0–I15.9 
Peripheral vascular disease 443.9 I21.0-I21.9, I23.0-I23.9, 
I70.0, I70.2-I70.9, I71.0-
I71.9, I73.9 
Hemiplegia 342.0 G81 
Dementia 294.20 G31.0 
Leukemia 208.0 C91-C96 
Lymphoma 202.8* C81-C88 
Alcohol use 303.9* F10.1, F10.2, F10.9 
Tobacco use 305.1 F17.2 
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EDUCATION 
• The University of Mississippi                                                        (August 2016 – May 2019)  
Masters Student, Department of Pharmacy Administration (Track: Health Economics 
and Outcomes Research)                                                   
 
Doctoral Student, Department of Pharmacy Administration (Track: Health Economics 
and Outcomes Research)                                                  (May 2019 – May 2021 (Expected)) 
 
CGPA: 3.98 
Relevant coursework: Pharmacoepidemiology, Pharmacoeconomics, Patient-reported 
Outcomes, Quantitative Methods in Psychology I & II, Mediation and Moderation, General 
Linear Models, Applied Multivariate Analysis, Primary Data Techniques, Secondary Data 
Techniques, Applied Political Research, Advanced Marketing and Patient Behavior, Drug 
Development and Marketing, Health Economics, Pharmaceutical and Healthcare Policy 
 
• University of Mumbai, India                                                          (August 2010 – May 2014) 
 Bachelor of Pharmacy (B. Pharm) 
KEY SKILLS 
• Proficient in retrospective database analyses of survey databases and administrative claims data  
• Possess a working knowledge of statistical software packages like SPSS, SAS, STATA, Instant 
Health Data (IHD) platform 
• Well versed in conceptualizing study designs and using advanced statistical techniques such as 
propensity score matching and survival analysis 
• Experience in economic modeling using TreeAge Pro 
• Experience in primary data techniques such as designing surveys using Qualtrics, conducting 
qualitative interviews, focus groups and content analyses
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Databases 
• Claims databases: 5% national Medicare sample, Mississippi Medicaid, Optum Humedica, 
Truven Health MarketScan 
• Public databases: National Health Interview Survey (NHIS), National Survey on Drug Use 
and Health (NSDUH) 
WORK EXPERIENCE 
• Research Assistant, Mississippi Medicaid Drug Utilization Review                   (June 2017 
– present) 
▪ Responsibilities include undertaking ad-hoc MS Medicaid Drug Utilization Review projects 
that investigate patient profiling, treatment patterns, resource utilization, adherence and 
quality measures using MS Medicaid data 
▪ SAS programming is used for data management and analyses 
 
• HEOR Intern, Alkermes Inc., MA                                                                            (June 
2018 – August 2018) 
▪ Evidence synthesis to support the clinical and safety value of a pipeline molecule in 
Major Depressive Disorder (MDD)  
▪ Targeted literature review to quantify the risk of tardive dyskinesia and akathisia in MDD 
patients treated with antipsychotics 
▪ Multiple feasibility assessments with Trvuen commercial database and Optum Humedica 
database on Instant Health Data (IHD) platform to estimate the patient counts and 
characteristics of patients with MDD and schizophrenia 
 
• Clinical Pharmacist, Tata Memorial Hospital, India                                        (August 2014 
– July 2015) 
▪ Preparation and monitoring of chemotherapy and supportive therapy to pediatric patients 
▪ Counseling the caregivers regarding the chemotherapy and supportive therapy 
RESEARCH EXPERIENCE 
Master’s Thesis  
• ‘Comparative Effectiveness and Safety of Non-Vitamin K Antagonists Oral 
Anticoagulants (NOACs) Versus Warfarin in Elderly Patients with Non-Valvular Atrial 
Fibrillation and Diabetes’ (Abstract submitted for ISPOR 2019, New Orleans, LA) 
▪ Patients initiating NOACs were matched 1:1 to warfarin patients on propensity score to 
balance demographic and clinical characteristics.  
▪ Primary effectiveness was measured as the risk of stroke/systemic embolism (SE) or 
myocardial infarction (MI). Primary safety measures included major bleeding - 
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intracranial hemorrhage (ICH), gastrointestinal bleeding (MGB), and bleeding from other 
sites (OB). 
▪ Cox proportional hazards models were used to estimate the effectiveness and safety 
outcomes of NOACs vs warfarin in the matched cohort. 
Posters 
• Korgaonkar S, Banahan B, Pittman E, Noble S. Effect of Depression on Medication Adherence 
to Asthma Controller Medications and Healthcare Resource Utilization in Severe Asthma 
Patients. International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd 
Annual International Meeting. Baltimore, Maryland.  May 19-23, 2018.  
• Korgaonkar S, Inguva S, Yang Y. Cost-Effectiveness of Mepolizumab Versus Omalizumab As 
an Adjunct Therapy in Patients with Uncontrolled Allergic Asthma. International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting. 
Baltimore, Maryland.  May 19-23, 2018.  
• Dunn T, Korgaonkar S, Ramachandran S. Association Between Stimulant Use and Misuse of 
Other Prescription Medications. International Society for Pharmacoeconomics and Outcomes 
Research (ISPOR) 23rd Annual International Meeting. Baltimore, Maryland.  May 19-23, 2018.  
• Korgaonkar S, Ward L, Pohl L, Nicks A. Exploring First Year Professional Pharmacy Students’ 
Perceptions and Knowledge of Older Adults. American Association of Colleges of Pharmacy 
Annual eeting, Boston, MA. July 21–25, 2018. 
 
Projects 
• Impact of Diverse Inclusion Criteria on Assessment of HEDIS Asthma Medication Ratio 
(AMR) Quality Measure in Mississippi Medicaid (Abstract submitted for ISPOR 2019, New 
Orleans, LA) 
▪ Sensitivity analyses using varied inclusion criteria was conducted to explore differential 
effect on AMR 
▪ Potential misclassification of acute asthma cases as persistent asthma cases was identified 
 
• Impact of Occupational Psychosocial Risk Factors on Frequent, Severe Low Back Pain in 
the US Working Population (Abstract submitted for ISPOR 2019, New Orleans, LA) 
▪ Multivariable logistic regression was used to measure the association between diverse 
work-related psychosocial risk factors and frequent, severe low back pain using 2015 NHIS 
database 
 
• Assessment first year professional pharmacy students’ perceptions of older adults 
▪ Designed a questionnaire based on Geriatric Attitudes Scale and Facts on Aging Quiz using 
Qualtrics platform to assess students’ perceptions pre- and post-interview with an older 
adult 
▪ Assessed the change in students’ perceptions pre- and post-interview with an older adult 
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• Long-acting reversible contraceptives (LARCs) and Depo-Provera utilization in 
Mississippi Medicaid population  
▪ Profiling of Mississippi Medicaid beneficiaries based on LARC and Depo-Provera 
utilization according to Code of Eligibility type 
 
• Pediatric use of multiple antipsychotics in Mississippi Medicaid population  
▪ Measured monthly use of multiple antipsychotics among children in Mississippi Medicaid 
population 
PROFESSIONAL AFFILIATIONS AND RESPONSIBILITIES 
• Secretary, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) - 
University of Mississippi student chapter (2017-2018) 
• Secretary, Rho Chi Honor Society- University of Mississippi Chapter, (2018-present) 
• Initiated into Phi Kappa Phi (2018) 
AWARDS 
• William E. Farlow Fellowship 2018-2019, Department of Pharmacy Administration, University 
of Mississippi, August 2018. 
• Member of runner-up team, Pharmacy Quality Alliance (PQA) - Healthcare Quality Innovation 
Challenge, Baltimore, Maryland.  May 2018. 
 
 
